Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Summary

• Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales.
• Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival.
• Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer.
• Cardiff's strong financial position, low cash burn, and favorable analyst ratings make it a compelling buy, with substantial growth potential in the mCRC market and beyond.

Mohammed Haneefa Nizamudeen/iStock via Getty Images

Thesis

Any day now, Cardiff (NASDAQ:CRDF) may announce objective response rate data of its Phase 2 trial for the first-line treatment of RAS-mutated metastatic colorectal cancer. This data has been awaited because of

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRDF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.